Condition
Diabetic Macular Edema Clinical Trials
Studies of diabetic macular edema, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 67Diabetic Retinal Disease
Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials.
- Trial name
- AS (NCT07567833)
- Testing
- Anti-Vascular Endothelial Growth Factor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
DME, Diabetic Macular Edema
Study of CU06-1004 in Patients With Daibetic Macular Edema
This phase 2b trial is a randomized, double-masked, parallel-group, multi-center study in approximately 156 patients with Diabetic Macular Edema to evaluate the efficacy and safety of CU06-1004 orally administered once daily for…
- Conditions
- DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- Trial name
- NCT07459829
- Testing
- CU06-1004
- Volunteers
- 156 people
- Sponsor
- Curacle Co., Ltd.
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 19 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Blepharoptosis, Age-Related Macular Degeneration
Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study
Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated…
- Conditions
- Blepharoptosis, Age-Related Macular Degeneration, Diabetic Macular Edema
- Trial name
- NCT07821450
- Testing
- Repeated intravitreal anti-VEGF injection with eyelid speculum
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Abdulkadir Küçük
Macular Edema
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take…
- Trial name
- NCT06962839
- Testing
- BI 1815368
- Where
- 97 sites in United States, China and 7 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina).
- Trial name
- NAAVIGATE (NCT07592273)
- Testing
- Surabgene Lomparvovec, Topical Steroid, Artificial Tears
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 576 people
- Sponsor
- AbbVie
Diabetic Macular Edema
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this…
- Trial name
- NCT07553429
- Testing
- Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
Suprachoroidal Triamcinolone Acetonide Monotherapy in Treatment-naive Center Involving Diabetic Macular Edema
The goal of this clinical trial is to evaluate whether a single injection of suprachoroidal triamcinolone acetonide (SCTA) improves visual outcomes in patients with treatment-naive diabetic macular edema involving the center of…
- Trial name
- SCTA CI-DME (NCT07870226)
- Testing
- Suprachoroidal triamcinolone acetonide injection
- Volunteers
- 25 people
- Sponsor
- Khyber Girls Medical College
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 82 sites in United States, China and 1 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics
Completed, with results posted
All 151Diabetic Macular Edema
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis®…
- Trial name
- PRO-169 (NCT05217680)
- Testing
- Bevacizumab, Lucentis®
- Where
- Mexico
- Volunteers
- 509 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Diabetic Macular Edema
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes.
- Trial name
- DRCR AC (NCT03321513)
- Testing
- intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
- Where
- 54 sites in United States
- Volunteers
- 270 people
- Sponsor
- Jaeb Center for Health Research
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema
Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)
The objective of this trial is to assess the safety, efficacy, and tolerability of RZ402 in patients with Diabetic Macular Edema.
- Trial name
- NCT05712720
- Testing
- Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402
- Where
- 32 sites in United States
- Volunteers
- 94 people
- Sponsor
- Rezolute
Diabetic Macular Edema
Extension Study of MYL-1701P-3001 for Safety and Efficacy
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
- Trial name
- NCT04674800
- Testing
- MYL-1701P, a proposed biosimilar to Eylea
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Mylan Pharmaceuticals Inc